Erika Heninger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erika Heninger has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Joshua Michael Lang
Carbone Cancer Center, University of Wisconsin, Madison, USA
59 shared publications - Shuang George Zhao
University of Wisconsin Department of Human Oncology, Madison, WI
56 shared publications - David Kosoff
Department of Medicine University of Wisconsin‐Madison Madison Wisconsin USA
30 shared publications - Anupama Singh
Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA
29 shared publications - Charlotte N. Stahlfeld
University of Pittsburgh Medical Center Mercy Hospital Pittsburgh Pennsylvania USA
29 shared publications - Christos E. Kyriakopoulos
University of Wisconsin–Madison 17 Department of Medicine Madison, Wisconsin
29 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (6) , 1522-1530
Identifying and addressing barriers to live primary prostate cancer cell research in Veterans
Increased comorbidities and unique service-related exposures among Veterans may contribute to unique tumor biology that can influence tumor behavior and response to treatment. Research that incorporates live cells from Veteran donors can support investigation of the genomic and transcriptomic biology of Veteran tumors as well as how those molecular alterations impact tumor function, such as growth, metastasis and treatment sensitivity. We conducted a systematic literature review to assess Veteran-focused prostate cancer studies published in the last decade that incorporate live primary cells. We found that in the past 10 years, 105 prostate cancer studies were published that utilized live primary cells from the general population compared to zero studies utilizing live primary cells from Veterans. Analysis of Veterans enrolled in a study utilizing live primary cells at the William S Middleton VA demonstrated that 94% of Veterans who were presented with a live cell biospecimen donation study ultimately enrolled. Furthermore, survey responses from Veterans enrolled in this study showed that 83% of Veterans found their research engagement to be a meaningful experience and 70% reported increased healthcare satisfaction as a result of their participation. These findings suggest that the lack of live cell prostate cancer research in Veterans appears to be due to a lack of research opportunities for Veterans and not a lack of Veteran interest in participation Finally, we demonstrate that implementation of an informatics-based patient screening strategy can potentially support more Veteran-focused studies by reducing participant screening time by 89%.
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (6) , 1522-1530
Open AccessIdentifying and addressing barriers to live primary prostate cancer cell research in Veterans
Increased comorbidities and unique service-related exposures among Veterans may contribute to unique tumor biology that can influence tumor behavior and response to treatment. Research that incorporates live cells from Veteran donors can support investigation of the genomic and transcriptomic biology of Veteran tumors as well as how those molecular alterations impact tumor function, such as growth, metastasis and treatment sensitivity. We conducted a systematic literature review to assess Veteran-focused prostate cancer studies published in the last decade that incorporate live primary cells. We found that in the past 10 years, 105 prostate cancer studies were published that utilized live primary cells from the general population compared to zero studies utilizing live primary cells from Veterans. Analysis of Veterans enrolled in a study utilizing live primary cells at the William S Middleton VA demonstrated that 94% of Veterans who were presented with a live cell biospecimen donation study ultimately enrolled. Furthermore, survey responses from Veterans enrolled in this study showed that 83% of Veterans found their research engagement to be a meaningful experience and 70% reported increased healthcare satisfaction as a result of their participation. These findings suggest that the lack of live cell prostate cancer research in Veterans appears to be due to a lack of research opportunities for Veterans and not a lack of Veteran interest in participation Finally, we demonstrate that implementation of an informatics-based patient screening strategy can potentially support more Veteran-focused studies by reducing participant screening time by 89%.
- Open Access
- 15 April 2026
- Published by Elsevier in SLAS Technology
- Vol. 38, 100421
Development of a novel fluid removal system to increase throughput and uniformity of fluid exchange in an open microfluidic culture platform
- 15 April 2026
- Published by Elsevier in SLAS Technology
- Vol. 38, 100421
Open AccessDevelopment of a novel fluid removal system to increase throughput and uniformity of fluid exchange in an open microfluidic culture platform
- Open Access
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1585
Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip
Cancer-associated fibroblasts (CAFs) are key regulators of the prostate tumor microenvironment (TME) with influence on disease progression and therapeutic response. CAFs originate from multiple precursors and retain remarkable plasticity while tumors evolve. Therefore, the CAF pool displays considerable functional heterogeneity, which is well-reflected in complex molecular signatures. However, overlapping biomarker patterns with other stromal subsets make it challenging to identify and assess the role of specific CAF subpopulations. Through reciprocal tumor–stroma interactions, CAFs promote extracellular matrix (ECM) remodeling, angiogenesis, metabolic reprogramming, and immune evasion, collectively fostering an adaptive niche that supports tumor survival, though some CAF subsets have been shown to support anti-tumor response. In prostate cancer (PCa), CAFs promote resistance to androgen receptor pathway inhibitor therapy, chemotherapy, and radiotherapy, emphasizing their potential value as therapeutic targets. However, CAF targeting has shown limited clinical benefit in PCa, due to complex, context-dependent CAF functions that make it challenging to exploit this unique stromal population for therapeutic gain. Recent advances in organ-on-a-chip (OOC) models offer new opportunities to investigate the mechanisms behind TME interactions and evaluate CAF-targeted strategies in physiologically relevant fully humanized environments. This review provides current insights into CAF heterogeneity and therapy resistance in PCa and highlights emerging translational OOC models to guide the development of more effective therapies to disrupt the TME.
- 5 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1585
Open AccessProstate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip
Cancer-associated fibroblasts (CAFs) are key regulators of the prostate tumor microenvironment (TME) with influence on disease progression and therapeutic response. CAFs originate from multiple precursors and retain remarkable plasticity while tumors evolve. Therefore, the CAF pool displays considerable functional heterogeneity, which is well-reflected in complex molecular signatures. However, overlapping biomarker patterns with other stromal subsets make it challenging to identify and assess the role of specific CAF subpopulations. Through reciprocal tumor–stroma interactions, CAFs promote extracellular matrix (ECM) remodeling, angiogenesis, metabolic reprogramming, and immune evasion, collectively fostering an adaptive niche that supports tumor survival, though some CAF subsets have been shown to support anti-tumor response. In prostate cancer (PCa), CAFs promote resistance to androgen receptor pathway inhibitor therapy, chemotherapy, and radiotherapy, emphasizing their potential value as therapeutic targets. However, CAF targeting has shown limited clinical benefit in PCa, due to complex, context-dependent CAF functions that make it challenging to exploit this unique stromal population for therapeutic gain. Recent advances in organ-on-a-chip (OOC) models offer new opportunities to investigate the mechanisms behind TME interactions and evaluate CAF-targeted strategies in physiologically relevant fully humanized environments. This review provides current insights into CAF heterogeneity and therapy resistance in PCa and highlights emerging translational OOC models to guide the development of more effective therapies to disrupt the TME.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S4. Biodistribution Study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S4. Biodistribution Study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
- Open Access
- 1 July 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-22
Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response
Bone is the most common site of prostate cancer metastasis, leading to significant morbidity, treatment resistance, and mortality. A major challenge in understanding treatment response is the complex, bone metastatic niche. Here, we report the first patient-specific microphysiological system (MPS) to incorporate six primary human stromal cell types found in the metastatic bone niche (mesenchymal stem cells, adipocytes, osteoblasts, osteoclasts, fibroblasts, and macrophages), alongside an endothelial microvessel, and prostate tumor epithelial spheroids in an optimized media that supports their viability and phenotype. We tested two standard of care drugs, darolutamide and docetaxel, in addition to sacituzumab govitecan (SG), currently in clinical trials for prostate cancer, demonstrating that the MPS accurately replicates androgen response sensitivity and captures stromal microenvironment-mediated resistance. This advanced MPS provides a robust platform for investigating the biological mechanisms of treatment response and for identification and testing of therapeutics to advance patient-specific MPS towards personalized clinical-decision making.
- 1 July 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-22
Open AccessEngineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response
Bone is the most common site of prostate cancer metastasis, leading to significant morbidity, treatment resistance, and mortality. A major challenge in understanding treatment response is the complex, bone metastatic niche. Here, we report the first patient-specific microphysiological system (MPS) to incorporate six primary human stromal cell types found in the metastatic bone niche (mesenchymal stem cells, adipocytes, osteoblasts, osteoclasts, fibroblasts, and macrophages), alongside an endothelial microvessel, and prostate tumor epithelial spheroids in an optimized media that supports their viability and phenotype. We tested two standard of care drugs, darolutamide and docetaxel, in addition to sacituzumab govitecan (SG), currently in clinical trials for prostate cancer, demonstrating that the MPS accurately replicates androgen response sensitivity and captures stromal microenvironment-mediated resistance. This advanced MPS provides a robust platform for investigating the biological mechanisms of treatment response and for identification and testing of therapeutics to advance patient-specific MPS towards personalized clinical-decision making.
- Open Access
- 1 April 2025
- Published by Springer Nature in Research Square
Live Cell Sorting of Differentiated Primary Human Osteoclasts Allows Generation of Transcriptomic Signature Matrix
Osteoclasts are specialized cells that degrade the bone matrix to create space for bone regeneration. During tumorigenesis, cancer cells metastasize to bone by disrupting bone’s natural remodeling cycle. However, the mechanisms underlying critical bone-tumor interactions are poorly understood due to challenges in isolating osteoclasts from human bone. Thus, the conventional method to obtain osteoclasts for in vitro studies is via the differentiation of peripheral blood monocytes, which results in mixed cultures containing progenitor cells and osteoclasts of varying maturity and nuclearity. Presently, we hypothesized that the transcriptomic signatures of mature, multinucleated osteoclasts are distinct from osteoclasts with fewer nuclei. We established a live cell biomarker expression-based sorting protocol to allow purification of mature osteoclasts while maintaining viability and function. We observed that mature, multinucleated osteoclasts were transcriptomically distinct from those with fewer nuclei and that mature osteoclasts showed higher expression of genes that are associated with osteoclast fusion and function.
- 1 April 2025
- Published by Springer Nature in Research Square
Open AccessLive Cell Sorting of Differentiated Primary Human Osteoclasts Allows Generation of Transcriptomic Signature Matrix
Osteoclasts are specialized cells that degrade the bone matrix to create space for bone regeneration. During tumorigenesis, cancer cells metastasize to bone by disrupting bone’s natural remodeling cycle. However, the mechanisms underlying critical bone-tumor interactions are poorly understood due to challenges in isolating osteoclasts from human bone. Thus, the conventional method to obtain osteoclasts for in vitro studies is via the differentiation of peripheral blood monocytes, which results in mixed cultures containing progenitor cells and osteoclasts of varying maturity and nuclearity. Presently, we hypothesized that the transcriptomic signatures of mature, multinucleated osteoclasts are distinct from osteoclasts with fewer nuclei. We established a live cell biomarker expression-based sorting protocol to allow purification of mature osteoclasts while maintaining viability and function. We observed that mature, multinucleated osteoclasts were transcriptomically distinct from those with fewer nuclei and that mature osteoclasts showed higher expression of genes that are associated with osteoclast fusion and function.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study